Evidence map›Paper›PMID 37173210›Full record

ArticleEuropean urology2023

Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.

Philip Sutera, Yang Song, Kim Van der Eecken, Amol C Shetty, Keara English, Theresa Hodges, Jinhee Chang, Valérie Fonteyne, Zaker Rana, Lei Ren and 19 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Article
  16. Article
  17. Review
  18. Review
  19. Stereotactic ablative radiotherapy (SABR) for pelvic nodal oligorecurrence in prostate cancer.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 10 institutions in 3 countries.

Philip SuteraDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yang SongInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
Kim Van der EeckenDepartment of Human Structure and Repair, Ghent University, Ghent, Belgium; Department of Pathology, Ghent University Hospital, Ghent, Belgium.
Amol C ShettyInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
Keara EnglishDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Theresa HodgesInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
Jinhee ChangDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
Valérie FonteyneDepartment of Radiation Oncology, Ghent University Hospital, Belgium.
Zaker RanaDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
Lei RenDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
Adrianna A MendesDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nicolaas LumenDepartment of Radiation Oncology, Ghent University Hospital, Belgium.
Louke DelrueDepartment of Radiology, Ghent University Hospital, Ghent, Belgium.
Sofie VerbekeDepartment of Pathology, Ghent University Hospital, Ghent, Belgium.
Kathia De ManDepartment of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium.
Daniel Y SongDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Kenneth PientaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Felix Y FengDepartments of Medicine, Urology and Radiation Oncology, University of California-San Francisco, San Francisco, CA, USA.
Steven JoniauDepartment of Radiation Oncology, Catholic University Leuven, Leuven, Belgium.
Tamara LotanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Barton LaneDepartment of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Ana KiessDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Steven RoweThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Martin PomperDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA; The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Theodore DeWeeseDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Matthew DeekDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.
Christopher SweeneySouth Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia.
Piet OstDepartment of Human Structure and Repair, Ghent University, Ghent, Belgium; Department of Radiation Oncology, Iridium Network, Antwerp, Belgium. Electronic address: piet.ost@ugent.be.
Phuoc T TranDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: phuoc.tran@som.umaryland.edu.
University of Maryland, Baltimore · USJohns Hopkins Medicine · USGhent University Hospital · BEJohns Hopkins University · USGhent University · BEKU Leuven · BECentre for Cancer Biology · AURutgers, The State University of New Jersey · USSidney Kimmel Comprehensive Cancer Center · USUniversity of California, San Francisco · US

Funding

Resource Sharing CoreU54CA273956 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Phuoc T. Tran · 2022 to 2026
$8.9M
Tumor-barcoding coupled with high-throughput sequencing of a novel chemoradiation resistant SCLC mouse modelU01CA231776 · NCI · JOHNS HOPKINS UNIVERSITY · PI HANN, CHRISTINE L., MARCHIONNI, LUIGI · 2018 to 2022
$3.9M
Integrating bioinformatics into multiscale models for hepatocellular carcinomaU01CA212007 · NCI · JOHNS HOPKINS UNIVERSITY · PI EWALD, ANDREW JOSEF, FERTIG, ELANA · 2018 to 2022
$3.2M
Opportunities for Pathology Trainees in Cancer ResearchT32CA193145 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANDERS, ROBERT A., EBERHART, CHARLES G · 2015 to 2025
$2.6M
NCI NIH HHS T32 CA193145NCI NIH HHS U01 CA212007NCI NIH HHS U01 CA231776NCI NIH HHS U54 CA273956
6 · The paper itself

Abstract

In metastatic castration-sensitive prostate cancer (mCSPC), disease volume plays an integral role in guiding treatment recommendations, including selection of docetaxel therapy, metastasis-directed therapy, and radiation to the prostate. Although there are multiple definitions of disease volume, they have commonly been studied in the context of metastases detected via conventional imaging (CIM). One such numeric definition of disease volume, termed oligometastasis, is heavily dependent on the sensitivity of the imaging modality. We performed an international multi-institutional retrospective review of men with metachronous oligometastatic CSPC (omCSPC), detected via either advanced molecular imaging alone (AMIM) or CIM. Patients were compared with respect to clinical and genomic features using the Mann-Whitney U test, Pearson's χ

Indexed as

Prostatic NeoplasmsCastrationDocetaxelGenomicsHumansMaleMolecular ImagingDocetaxelGenomicsMolecular imagingOligometastatic prostate cancer

Identifiers

PMID37173210
PMCPMC10636237
OpenAlexW4376598533

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.